BGM Group Ltd. (BGM)

Market Cap	53.72M -96.9%
Revenue (ttm)	n/a -46.0%
Net Income	n/a
EPS	n/a
Shares Out	183.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,693
Open	0.2930
Previous Close	0.2930
Day's Range	0.2841 - 0.2982
52-Week Range	0.2560 - 17.1700
Beta	1.46
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About BGM

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 12, 2021
• Country: China
• Stock Exchange: NASDAQ
• Ticker Symbol: BGM
• Website: https://www.bgmgroupltd.com

Financial Performance

In 2024, BGM Group's revenue was $25.10 million, a decrease of -45.99% compared to the previous year's $46.47 million. Losses were -$1.44 million, -81.46% less than in 2023.